The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients (Q87425582)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Xinju Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Tingting Hu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Zhiyuan Wu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Zhihua Kang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Weiwei Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ming Guan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

29 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hematology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

611-616

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

10 March 2020

cites work

1 reference

12 December 2020

Targeting JAK2 in the therapy of myeloproliferative neoplasms

1 reference

12 December 2020

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

1 reference

12 December 2020

Janus kinases in immune cell signaling

1 reference

12 December 2020

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

12 December 2020

Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera

1 reference

12 December 2020

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

1 reference

12 December 2020

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

1 reference

12 December 2020

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

1 reference

12 December 2020

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden

1 reference

12 December 2020

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

1 reference

12 December 2020

The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

1 reference

12 December 2020

Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice

1 reference

12 December 2020

Genetics of the myeloproliferative neoplasms

1 reference

12 December 2020

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

1 reference

12 December 2020

Rapid genotyping of APOA5 -1131T>C polymorphism using high resolution melting analysis with unlabeled probes.

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms

1 reference

12 December 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

12 December 2020

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

1 reference

12 December 2020

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.

1 reference

12 December 2020

High-throughput genotyping of mannose-binding lectin variants using high-resolution DNA-melting analysis

1 reference

12 December 2020

10.1007/S12185-012-1169-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference